Victory Pharma receives $45 Million equity financing
Printer Print Email Email
San Diego: Victory Pharma, a privately held specialty pharmaceutical company, has closed on a $45 million equity financing facility led by Essex Woodlands Health Ventures. Ampersand Ventures, an existing investor, also participated in the financing. Proceeds will be used to support future growth initiatives, including product acquisitions. As part of the transaction, Victory announced that Scott Barry, Essex Partner, has joined its Board of Directors. President and CEO of Victory, Matt Heck stated. "Essex's experience in building successful specialty pharmaceutical companies, significant fund size and reputation as a high quality, health care investor serve to further position Victory for its next phase of growth." Heck continued, "Importantly, in the course of the financing process, we found there is a good cultural fit between the Company and Essex, which was also very important to us." On the occasion, Barry remarked, "Essex is excited to invest in such an experienced and successful management team which has demonstrated an ability to execute commercially with the Company's lead product NAPRELAN and at prior companies. Victory is a rapidly growing, profitable business that we see as an excellent growth equity platform upon which to build a substantial specialty pharmaceutical company."

Digital Supply Chain Transformation – Winning the AI/ML Way